Licensing
Gene Bridges GmbH has announced that Chugai Pharmaceutical Co., Ltd. of Tokyo, Japan, has expanded the commercial license agreement existing since 2005 for the use of its Red/ET recombination technology.
The Red/ET recombination technology, patented in Japan under the title ‘Novel DNA Cloning Method’, is a method for generating targeting vectors, or modifying E. coli chromosomes. “Red/ET is fast becoming the standard DNA engineering technology used in industry and academia worldwide,” claimed Gary Stevens, CEO of Gene Bridges. “Having recently also licensed Red/ET to Daiichi Sankyo and Takeda we are delighted to be signing this amendment to another leading Japanese pharmaceutical company.”
Gene Bridges was founded in 2000 as a spin-out from the European Molecular Biology Laboratory in Heidelberg, Germany.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
